Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_assertion description "[Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_assertion evidence source_evidence_literature NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_assertion SIO_000772 18344568 NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_assertion wasDerivedFrom befree-2016 NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_assertion wasGeneratedBy ECO_0000203 NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.
- befree-2016 importedOn "2016-02-19" NP660956.RA00QmR0Ds1aHfI1awpLJm-94n0A3M1A_ey8rlPy_gWgQ130_provenance.